Pancreatic Polypeptide (human) trifluoroacetate salt structure
|
Common Name | Pancreatic Polypeptide (human) trifluoroacetate salt | ||
|---|---|---|---|---|
| CAS Number | 75976-10-2 | Molecular Weight | 4181.71 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C185H287N53O54S2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Pancreatic Polypeptide (human) trifluoroacetate saltPancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/Y5 receptor agonist. |
| Name | Pancreatic Polypeptide(Human) |
|---|---|
| Synonym | More Synonyms |
| Description | Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/Y5 receptor agonist. |
|---|---|
| Related Catalog | |
| Target |
Neuropeptide Y (NPY) Y4/Y5 receptor[1] |
| In Vitro | Human pancreatic polypeptide (hPP) is one such peptide, being released postprandially from F cells of the pancreatic islets depending on caloric load, food consumption and circadian rhythm. It is a C-terminally amidated 36 amino acid peptide with a characteristic hairpin-like pancreatic polypeptide (PP)-fold and acts at the Y4 receptor to induce satiety and delay gastric emptying and motility[1]. Addition of the human pancreatic polypeptide (hPP) (10 nM-1 μM) results in a significant, dose-dependent reduction in both basal and stimulated release. Human pancreatic polypeptide (hPP) can also inhibit basal and stimulated NPY release with a pharmacological profile suggesting a role for Y4 presynaptic receptors[2]. |
| References |
| Molecular Formula | C185H287N53O54S2 |
|---|---|
| Molecular Weight | 4181.71 |
| Storage condition | -15°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| MFCD00081812 |
| Pancreatic Polypeptide (human) |
| Pancreatic Polypeptide, human |